MA49840A - Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) - Google Patents

Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Info

Publication number
MA49840A
MA49840A MA049840A MA49840A MA49840A MA 49840 A MA49840 A MA 49840A MA 049840 A MA049840 A MA 049840A MA 49840 A MA49840 A MA 49840A MA 49840 A MA49840 A MA 49840A
Authority
MA
Morocco
Prior art keywords
prmt5
inhibitors
protein arginine
arginine methyltransferase
selective protein
Prior art date
Application number
MA049840A
Other languages
English (en)
French (fr)
Inventor
Michael Hawkins
Hong Lin
Juan Luengo
Rupa Shetty
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MA49840A publication Critical patent/MA49840A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
MA049840A 2017-08-09 2018-08-09 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) MA49840A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543141P 2017-08-09 2017-08-09
US201862630581P 2018-02-14 2018-02-14
US201862664442P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA49840A true MA49840A (fr) 2020-06-17

Family

ID=63405398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049840A MA49840A (fr) 2017-08-09 2018-08-09 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Country Status (18)

Country Link
US (4) US10570140B2 (https=)
EP (2) EP3939986A1 (https=)
JP (1) JP2020530496A (https=)
KR (1) KR20200036922A (https=)
CN (1) CN111527099B (https=)
AU (1) AU2018313910B2 (https=)
BR (1) BR112020002736A2 (https=)
CA (1) CA3072439A1 (https=)
DK (1) DK3665179T3 (https=)
ES (1) ES2885180T3 (https=)
IL (1) IL272519B (https=)
MA (1) MA49840A (https=)
MX (1) MX2020001598A (https=)
PL (1) PL3665179T3 (https=)
PT (1) PT3665179T (https=)
UA (1) UA126481C2 (https=)
WO (1) WO2019032859A1 (https=)
ZA (1) ZA202000773B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3665179T3 (pl) * 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
BR112020018636A2 (pt) 2018-03-14 2020-12-29 Prelude Therapeutics, Incorporated Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5)
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020033288A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
EP3947387B1 (en) * 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
WO2020206299A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
KR20220016194A (ko) * 2019-05-30 2022-02-08 앤젝스 파마수티컬, 인크. Prmt5 억제제로서의 헤테로시클릭 화합물
WO2021055797A1 (en) * 2019-09-18 2021-03-25 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
AU2020372002A1 (en) * 2019-10-21 2022-05-26 Accent Therapeutics, Inc Mettl3 modulators
UA128683C2 (uk) 2019-10-22 2024-09-25 Люпін Лімітед Фармацевтична комбінація на основі інгібіторів prmt5
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677A (zh) 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
US11685744B2 (en) 2020-09-21 2023-06-27 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2022125735A1 (en) 2020-12-10 2022-06-16 Prelude Therapeutics Incorporated Processes for making prmt5 inhibitors
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors
IL316942A (en) 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
WO2023001133A1 (zh) * 2021-07-20 2023-01-26 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
WO2023141571A1 (en) 2022-01-21 2023-07-27 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
US20240018136A1 (en) 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
EP4496627A1 (en) 2022-03-23 2025-01-29 Prelude Therapeutics Incorporated Polymorphic compounds and uses thereof
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
US20240352029A1 (en) 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
DE102010060118A1 (de) * 2010-10-22 2012-04-26 Röhm Gmbh Stirnseitenmitnehmer
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
TWI674262B (zh) * 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
UA118548C2 (uk) * 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
EP2970136A1 (en) * 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
JP6510485B2 (ja) * 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Prmt5インヒビターおよびそれらの使用方法
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
KR101719881B1 (ko) * 2014-12-22 2017-03-24 삼성전기주식회사 렌즈 모듈
JP6584521B2 (ja) * 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
PE20181894A1 (es) 2016-03-10 2018-12-11 Janssen Pharmaceutica Nv Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PL3665179T3 (pl) 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS

Also Published As

Publication number Publication date
CA3072439A1 (en) 2019-02-14
IL272519B (en) 2022-05-01
JP2020530496A (ja) 2020-10-22
PT3665179T (pt) 2021-09-10
EP3665179A1 (en) 2020-06-17
CN111527099B (zh) 2024-03-22
KR20200036922A (ko) 2020-04-07
BR112020002736A2 (pt) 2020-07-28
ES2885180T3 (es) 2021-12-13
EP3665179B1 (en) 2021-06-09
US20220153747A1 (en) 2022-05-19
EP3939986A1 (en) 2022-01-19
US20200361946A1 (en) 2020-11-19
WO2019032859A1 (en) 2019-02-14
MX2020001598A (es) 2020-10-28
CN111527099A (zh) 2020-08-11
US10570140B2 (en) 2020-02-25
DK3665179T3 (da) 2021-08-16
US20190048014A1 (en) 2019-02-14
US11078205B2 (en) 2021-08-03
US20200148692A1 (en) 2020-05-14
US11208416B2 (en) 2021-12-28
UA126481C2 (uk) 2022-10-12
PL3665179T3 (pl) 2021-11-29
AU2018313910B2 (en) 2022-12-08
AU2018313910A1 (en) 2020-03-05
ZA202000773B (en) 2022-07-27
IL272519A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
MA49840A (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EP3952874A4 (en) SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3679031A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
MA53287A (fr) Inhibiteurs de prmt5
EP3518934A4 (en) Inhibitors of adenosine 5'-nucleotidase
MA52005A (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EP3423451A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
MA47323A (fr) Protéines de liaison icos
EP3801503A4 (en) INHIBITORS OF SARM1
EP3946352A4 (en) SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
DK3319939T3 (da) Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
EP4063358C0 (en) HISTONE METHYLTRANSFERASE INHIBITORS
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
EP3654875C0 (en) ARTHRODESIS SYSTEM OF A JOINT
EP3706747A4 (en) PRMT5 INHIBITORS
EP3817736A4 (en) PIKFYVE INHIBITORS
MA52809A (fr) Inhibiteurs de sarm1
EP3746430A4 (en) INHIBITORS OF PROTEIN ARGININE DEIMINASES
IL287309A (en) Electrosurgical system
IL287160A (en) Electrosurgical system
EP3833668A4 (en) PRMT5 INHIBITORS
EP3833669A4 (en) PRMT5 INHIBITORS
EP3706742A4 (en) PRMT5 INHIBITORS
DK3737402T5 (da) Modificeret protein
DK3574100T3 (da) Cellefrit proteinsyntesesystem